Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology

Sickle Cell Patients Treated With Endari® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline Adverse Events Among These Patients from French Guiana and Qatar were Few and Mild TORRANCE, Calif., April 7, 2022...

Click to view original post